GALECTIN THERAPEUTICS INC
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Research and development | $14.3M | $36.6M | $32.1M | $31.7M | $23.8M |
| Operating expenses | $20.1M | $42.4M | $38.1M | $38.4M | $30.2M |
| Operating income | -$20.1M | -$42.4M | -$38.1M | -$38.4M | -$30.2M |
| Interest expense | $7.3M | $5.5M | $2.8M | $1.0M | $489,000 |
| Income tax expense | $0 | $0 | — | — | — |
| Net income | -$30.8M | -$47.0M | -$41.1M | -$38.8M | -$30.5M |
| Balance Sheet | |||||
| Cash and equivalents | $17.7M | $15.1M | $25.7M | $18.6M | $39.6M |
| Current assets | $19.4M | $17.3M | $27.7M | $20.6M | $41.8M |
| Total assets | $19.5M | $17.5M | $28.2M | $21.3M | $41.8M |
| Current liabilities | $8.0M | $35.4M | $15.7M | $13.0M | $9.0M |
| Total liabilities | $145.7M | $120.6M | $88.4M | $53.5M | $39.2M |
| Stockholders' equity | -$127.9M | -$104.8M | -$62.0M | -$33.9M | $893,000 |
| Cash Flow Statement | |||||
| Cash from operations | -$23.9M | -$41.8M | -$33.0M | -$31.1M | -$24.3M |
| Depreciation and amortization | — | $0 | $0 | $0 | $0 |
| Stock-based compensation | $1.7M | $2.4M | $2.3M | $2.9M | $2.1M |
| Impairments | $0 | $0 | $0 | $0 | $0 |
Shares outstanding 65.9M
Annual filing data through FY ended December 31, 2025; float as of July 12, 2026.